Durham drug developer Chimerix (Nasdaq: CMRX) will enjoy patent protection on its drugs through 2034.

The U.S. Patent and Trademark Office allowed Chimerix a patent covering a method of synthesis and the commercial morphic form of brincidofovir, the drug developer’s lead product. With the addition of this most recent patent, composition of matter coverage for brincidofovir in the U.S. is expected to extend to October 2034.

In tests, brincidofovir has shown antiviral activity against all five families…